201 incidensen af træthed, feber, myalgi, neutropeni/ anæmi, anoreksi, kvalme og opkastning, diarré, kulderystelser, influenzalignende symptomer, depression, alopeci, smagsforstyrrelser og svimmelhed i en undersøgelse af højdosis adjuverende IntronA behandling hos patienter med melanom større end i hepatitis C undersøgelserne.
For example, in a trial of high-dose adjuvant IntronA treatment in patients with melanoma, incidences of fatigue, fever, myalgia, neutropaenia/anaemia, anorexia, nausea and vomiting, diarrhoea, chills, flu- like symptoms, depression, alopecia, altered taste, and dizziness were greater than in the hepatitis C trials.